AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 APR 11 - (NewsRx.com & NewsRx.net) --
The second International AIDS Vaccine Initiative (IAVI-) sponsored preventive HIV vaccine designed specifically for Africa entered human trials on March 14, 2001, in the U.K. with the inoculation of five volunteers.
Testing of the vaccine will begin later in Kenya.
The MVA, or modified vaccinia Ankara, vaccine is the first of its kind to be tested in humans. Derived from a virus used in smallpox immunization, the vaccine aims to stimulate the production of a certain kind of immune cell that kills other cells infected with HIV. The vaccine is attenuated through genetic modification so it cannot cause infection with either HIV or pox illnesses.
The MVA candidate is designed to be used in combination with an IAVI-sponsored DNA vaccine already in human testing in both the U.K. and Kenya. Both vaccines are based on HIV subtype A, the strain of the virus circulating in East Africa, and are the first preventive AIDS ...
Source: HighBeam Research, Second IAVI-Sponsored Vaccine For Africa Enters Human Trials In...